Your session is about to expire
← Back to Search
Angiotensin Receptor Neprilysin Inhibitor
one arm for Heart Failure
N/A
Waitlist Available
Led By Gordon W Moe, MD, MSc
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 weeks, 4 weeks, 6 months, and 12 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Summary
The purpose of this study is to compare the changes in B-type Natriuretic Peptide (BNP) and amino-terminal fragment of proBNP (NT-proBNP) in outpatients managed in the heart failure (HF) clinic initiated on the Angiotensin Receptor Neprilysin Inhibitor (Entresto) and directly compare the prognostic values of BNP and NT-proBNP in patients admitted with acute decompensated HF.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 2 weeks, 4 weeks, 6 months, and 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 weeks, 4 weeks, 6 months, and 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
In Patient Protocol
Out Patient Protocol
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: one armExperimental Treatment1 Intervention
One arm study patients where NT-proBNP and BNP tests will be monitored.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sacubitril
FDA approved
Find a Location
Who is running the clinical trial?
Alere, Inc.Industry Sponsor
3 Previous Clinical Trials
1,189 Total Patients Enrolled
1 Trials studying Heart Failure
930 Patients Enrolled for Heart Failure
Unity Health TorontoLead Sponsor
556 Previous Clinical Trials
454,106 Total Patients Enrolled
12 Trials studying Heart Failure
7,183 Patients Enrolled for Heart Failure
Gordon W Moe, MD, MScPrincipal InvestigatorUnity Health Toronto
Share this study with friends
Copy Link
Messenger